Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease

详细信息    查看全文

• 作者：Eman El Eter (1)
  Abeer Al Masri (1)
  Shahid Habib (1)
  Hana Al Zamil (1)
  Ahmed Al Hersi (2)
  Fawaz Al Hussein (3)
  Mohamed Al Omran (4)
  
• 关键词：Peroxiredoxins ; Oxidative stress ; Atherosclerosis ; Diabetes ; Endothelial dysfunction ; ABI
• 刊名：Cell Stress and Chaperones
• 出版年：2014
• 出版时间：March 2014
• 年：2014
• 卷：19
• 期：2
• 页码：173-181
• 全文大小：442 KB
• 参考文献：1. Austin M, Hokanson JE, Edwards KL (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81:7B-2B, PMID: 9526807 CrossRef
  2. Bast A, Wolf G, Oberbaumer I, Walther R (2002) Oxidative and nitrosative stress induces peroxiredoxins in pancreatic beta cells. Diabetologia 45:867-76, PMID:12107731 CrossRef
  3. Bergamini CM, Gambetti S, Dondi A, Cervellati C (2004) Oxygen, reactive oxygen species and tissue damage. Curr Pharm Des 10:1611-626. doi:10.2174/1381612043384664 CrossRef
  4. Brevetti G, Schiano V, Chiariello M (2006) Cellular adhesion molecules and peripheral arterial disease. Vasc Med 11:39-7. doi:10.1191/1358863x06vm645ra CrossRef
  5. Conway JP, Kinter M (2006) Dual role of peroxiredoxin1 in macrophage-derived foam cells. J Biol Chem 281:27991-8001. doi:10.1074/jbc.M605026200 CrossRef
  6. Doobay AV, Anand SS (2005) Sensitivity and specificity of the ankle-brachial index to predict future cardiovascular outcomes: a systematic review. Arterioscler Thromb Vasc Biol 25:1463-469. doi:10.1161/01.ATV.0000168911.78624.b7 CrossRef
  7. Grant EG, Benson CB, Moneta GL et al (2003) Carotid artery stenosis gray-scale and Doppler US diagnostic Society of Radiologists in Ultrasound Consensus Conference. Radiology 229(2):340-46. doi:10.1148/radiol.2292030516 CrossRef
  8. Grundy SM (1998) Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 81:18B-5B, PMID:9526809 CrossRef
  9. Hui DY (2012) Phospholipase A2 enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol 23(3):235-40. doi:10.1097/MOL.0b013e328351b439 CrossRef
  10. Jang HH, Lee KO, Chi YH et al (2004) Two enzymes in one; two yeast peroxiredoxins display oxidative stress-dependent switching from a peroxidase to a molecular chaperone function. Cell 117(5):625-35 CrossRef
  11. Khawaja FJ, Kullo IJ (2009) Novel markers of peripheral arterial disease. Vasc Med 14(4):381-92. doi:10.1177/1358863X09106869 CrossRef
  12. Kisucka J, Chauhan AK, Patten IS et al (2008) Peroxiredoxin 1 prevents excessive endothelial activation and early atherosclerosis. Circ Res 103:598-05. doi:10.1161/CIRCRESAHA.108.174870 CrossRef
  13. Kumin A, Schafer M, Epp N et al (2007) Peroxiredoxin 6 is required for blood vessel integrity in wounded skin. J Cell Biol 179(4):747-60. doi:10.1083/jcb.200706090 CrossRef
  14. Lien YC, Feinstein SI, Dodia C, Fisher AB (2012) The roles of peroxidase and phospholipase A2 activities of peroxiredoxin 6 in protecting pulmonary microvascular endothelial cells against peroxidative stress. Antioxid Redox Signal 16(5):440-51. doi:10.1089/ars.2011.3950 CrossRef
  15. Lockhart CJ, Hamilton PK, McVeigh KA, McVeigh GE (2008) A cardiologist view of vascular disease in diabetes. Diabetes, Obesity and Metabolism 10(4):279-92. doi:10.1111/j.1463-1326.2007.00727.x CrossRef
  16. Lui G, Feinstein SI, Wang Y et al (2010) Comparison of glutathione peroxidase 1 and peroxidase 6 in protection against oxidative stress in the mouse lung. Free Radic Biol Med 49(7):1172-181. doi:10.1016/j.freeradbiomed.2010.07.002 CrossRef
  17. Madamanchi NR, Vendrov A, Runge MS (2005) Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29-8. doi:10.1161/01.ATV.0000150649.39934.13 CrossRef
  18. Mah E, Bruno RS (2012) Postprandial hyperglycemia on vascular endothelial function: mechanisms and consequences. Nutr Res 10:727-40. doi:10.1016/j.nutres.2012.08.002 CrossRef
  19. Martinez-Pinna R, Ramos-Mozo P, Madrigal-Matute J et al (2011) Identification of peroxiredoxin-1 as a novel biomarker of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 31(4):935-43. doi:10.1161/ATVBAHA.110.214429 CrossRef
  20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412-19, PMID: 3899825 CrossRef
  21. Moon EY, Noh YW, Han YH et al (2006) T lymphocytes and dendritic cells are activated by the deletion of peroxiredoxin II (PrxII) gene. Immunol Lett 102:184-90. doi:10.101016/j.imlet.2005.09.003 CrossRef
  22. Mowbray AL, Kang DH, Rhee SG, Kang SW, Jo H (2008) Laminar sheer stress up-regulates peroxiredoxins (PRDX) in endothelial cells: PRDX 1 as a mechanosensitive antioxidant. J Biol Chem 283:1622-627 CrossRef
  23. Neumann CA, Krause DS, Carman CV et al (2003) Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defense and tumor suppression. Nature 424:561-65. doi:10.1038/nature01819 CrossRef
  24. Okado-Matsumoto A, Matsumoto A, Fujii J, Taniguchi N (2000) Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J Biochem 127(3):493-01, PMID:10731722 CrossRef
  25. Park JG, Oh GT (2011) The role of peroxidases in the pathogenesis of atherosclerosis. BMB 44(8):497-05, PMID: 21871172 CrossRef
  26. Park JG, Yoo JY, Jeong SJ et al (2011) Peroxiredoxin 2 deficiency exacerbates atherosclerosis in apolipoprotein E-deficient mice. Cir Res. doi:10.1161/CIRCRESAHA.111.245530
  27. Rhee SG, Chae HZ, Kim K (2005) Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med 38:1543-552. doi:10.1016/j.freeradbiomed.2005.02.026 CrossRef
  28. Schulte J, Struck J, Kohrle J, Muller B (2011) Circulating levels of peroxiredoxin 4 as a novel biomarker of oxidative stress in patients with sepsis. Shock 35(5):460-65. doi:10.1097/SHK.0b01.3e3182115f40 CrossRef
  29. Silvestro A, Scopacasa F, Ruocco A et al (2003) Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med 8(4):225-32. doi:10.1191/1358863x03vm503oa CrossRef
  30. Ting HJ, Stice JP, Schaff UY et al (2007) Triglycerides-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha. Circ Res 100:381-90. doi:10.1161/01.RES.0000258023.76515.a3 CrossRef
  31. Wang X, Phelan SA, Forsman-Semb K et al (2003) Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J Biol Chem 278:25179-5190. doi:10.1074/jbc.M302706200 CrossRef
  32. Yu S, Mu Y, Ao J, Chen X (2010) Peroxiredoxin IV regulates pro-inflammatory responses in large yellow croaker ( / Pseudosciaena crocea) and protects against bacterial challenge. J Proteome Res 9(3):1424-436. doi:10.1021/pr900961x CrossRef
  
• 作者单位：Eman El Eter (1)
  Abeer Al Masri (1)
  Shahid Habib (1)
  Hana Al Zamil (1)
  Ahmed Al Hersi (2)
  Fawaz Al Hussein (3)
  Mohamed Al Omran (4)
  
  1. Physiology Department, Medical College and King Khalid University Hospital, King Saud University, P.O. BOX 2925(29), Riyadh, 11464, Saudi Arabia
  2. Cardiology Department, King Saud University, Riyadh, Saudi Arabia
  3. Neurology Department, King Saud University, Riyadh, Saudi Arabia
  4. Vascular Surgery Department, King Saud University, Riyadh, Saudi Arabia
  
• ISSN：1466-1268

文摘

Peroxiredoxins, a group of antioxidant protein enzymes (PRDX1 to 6), are reported as antiatherogenic factors in animals; however, human studies are lacking. The present work aims to provide baseline data regarding the phenotype of PRDX1, 2, 4, and 6 in diabetic patients with peripheral atherosclerosis disease (PAD) and their relation to endothelial dysfunction (ED) and disease severity. Plasma levels of PRDX1, 2, 4, and 6 and markers of endothelial dysfunction (ICAM-1 and VCAM-1) were measured using ELISA in 55 type 2 diabetic patients having PAD and 25 healthy subjects. Ankle–brachial index (ABI), body mass index (BMI), triglycerides (TG), total cholesterol, HbA1c, and insulin resistance (HOMA IR) were measured. PRDX1, 2, 4, and 6 levels were significantly higher in patients compared to controls (PRDX1 21.9?±-.71 vs 16.8?±-.9?ng/ml, P-lt;-.001, PRDX2 36.5?±-4.83 vs 20.4?±-.61?ng/ml, P-lt;-.001, PRDX4 3,840?±-,440 vs 2,696?±-,972?pg/ml, P-lt;-.005, PRDX6 311?±-10 vs 287.9?±-14?pg/ml, P-lt;-.05). PRDX1 and PRDX4 correlated negatively with ABI (r-??0.273, P-lt;-.05 and r-??0.28, P-lt;-.05, respectively), while PRDX1 and PRDX2 correlated positively with HOMA/IR and TG (r--.276, P-lt;-.01 and r--.295, P-lt;-.01, respectively). ICAM-1 was associated with PRDX2 and log PRDX6 (r--.345, P--.0037 and r--.344, P--.0038). Our results provide strong links among PRDXs, ED, and severity of PAD in diabetic patients which warrants further evaluation to clarify whether high circulating levels of PRDXs are a consequence of chronic atherosclerotic disease or a predisposing factor for later cardiovascular events.